These reports support the idea that blocking S1PR2 may have beneficial effects on neuroinflammation and cognitive and motor function in different pathologies, including hyperammonemia, hepatic encephalopathy and Alzheimer’s disease. Here, S1PR2 is linked to early-onset autosomal dominant Alzheimer disease.